{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:02:59Z","timestamp":1785358979112,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2025.104456","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:23:31Z","timestamp":1767831811000},"page":"104456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elenagen, a p62\/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial"],"prefix":"10.1016","volume":"36","author":[{"given":"Sergei","family":"Krasny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yauheni","family":"Baranau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Bakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Polyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Streltsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Zharkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliona","family":"Filimonava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-5379","authenticated-orcid":false,"given":"Gabriel","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-4718","authenticated-orcid":false,"given":"Vladimir","family":"Gabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.104456_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"9698","key":"10.1016\/j.ijgc.2025.104456_bib2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.ijgc.2025.104456_bib3","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"suppl 8","key":"10.1016\/j.ijgc.2025.104456_bib4","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.104456_bib5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.ijgc.2025.104456_bib6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cell.2016.09.030","article-title":"p62 in cancer: signaling adaptor beyond autophagy","volume":"167","author":"Moscat","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ijgc.2025.104456_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10555-025-10250-w","article-title":"p62\/SQSTM1 in cancer: phenomena, mechanisms, and regulation in DNA damage repair","volume":"44","author":"Yang","year":"2025","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.ijgc.2025.104456_bib8","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-21-2599","article-title":"U.S. FDA drug approvals for gynecological malignancies: a decade in review","volume":"28","author":"Arora","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.ijgc.2025.104456_bib9","first-page":"539","article-title":"P62\/SQSTM1 beyond autophagy: physiological role and therapeutic applications in laboratory and domestic animals","volume":"12","author":"Sabbieti","year":"2022","journal-title":"Life (Basel)"},{"issue":"8","key":"10.1016\/j.ijgc.2025.104456_bib10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/cancers11081182","article-title":"NF-\u03baB signaling in ovarian cancer","volume":"11","author":"Harrington","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ijgc.2025.104456_bib11","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.18632\/oncotarget.1397","article-title":"Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector","volume":"4","author":"Venanzi","year":"2013","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.ijgc.2025.104456_bib12","doi-asserted-by":"crossref","first-page":"12803","DOI":"10.18632\/oncotarget.2516","article-title":"Pilot study of p62 DNA vaccine in dogs with mammary tumors","volume":"5","author":"Gabai","year":"2014","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.ijgc.2025.104456_bib13","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.18632\/aging.102486","article-title":"p62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity","volume":"11","author":"Venanzi","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"32","key":"10.1016\/j.ijgc.2025.104456_bib14","doi-asserted-by":"crossref","first-page":"53730","DOI":"10.18632\/oncotarget.16574","article-title":"Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors","volume":"8","author":"Ponomarenko","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijgc.2025.104456_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2025.1519881","article-title":"Efficacy of P62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study","volume":"12","author":"Gabai","year":"2025","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.ijgc.2025.104456_bib16","doi-asserted-by":"crossref","unstructured":"Gabai V, Bakin E, Langs MH, et al. Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis. Preprint Posted online November 20, 2024. Research Square rs.3.rs-5461004\/v1. doi:10.21203\/rs.3.rs-5461004\/v1.","DOI":"10.21203\/rs.3.rs-5461004\/v1"},{"issue":"2","key":"10.1016\/j.ijgc.2025.104456_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jcp.30937","article-title":"p62\/SQSTM1 indirectly mediates remote multipotent mesenchymal cells and rescues bone loss and bone marrow integrity in ovariectomized rats","volume":"238","author":"Agas","year":"2023","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ijgc.2025.104456_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygcen.2022.114009","article-title":"P62\/SQSTM1 enhances osteogenesis and attenuates inflammatory signals in bone marrow microenvironment","volume":"320","author":"Agas","year":"2022","journal-title":"Gen Comp Endocrinol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.104456_bib19","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.18632\/oncotarget.2884","article-title":"Plasmid DNA-coding p62 as a bone effective anti-inflammatory\/anabolic agent","volume":"6","author":"Sabbieti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijgc.2025.104456_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1343023","article-title":"Clinical efficacy of plasmid encoding p62\/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial","volume":"14","author":"Krasny","year":"2024","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.104456_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"18","key":"10.1016\/j.ijgc.2025.104456_bib22","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/1078-0432.CCR-22-0560","article-title":"Statistical considerations for analyses of time-to-event endpoints in oncology clinical trials: illustrations with CAR-T immunotherapy studies","volume":"28","author":"Li","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ijgc.2025.104456_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"suppl 6","key":"10.1016\/j.ijgc.2025.104456_bib24","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.104456_bib25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.104456_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.111161","article-title":"Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: a collaborative multi-institutional study","volume":"52","author":"Tesei","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"10496","key":"10.1016\/j.ijgc.2025.104456_bib27","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2025.104456_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2024.11.010","article-title":"Analysis of real world FR\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers","volume":"192","author":"Previs","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.104456_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/or.2022.10568","article-title":"NF-\u03baB signaling in tumor pathways focusing on breast and ovarian cancer","volume":"16","author":"Devanaboyina","year":"2022","journal-title":"Oncol Rev."},{"issue":"6","key":"10.1016\/j.ijgc.2025.104456_bib32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2559.2010.03544.x","article-title":"Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma","volume":"56","author":"Darb-Esfahani","year":"2010","journal-title":"Histopathology"},{"issue":"21","key":"10.1016\/j.ijgc.2025.104456_bib33","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/sj.onc.1206390","article-title":"Role of NF- kappaB and Akt\/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death","volume":"22","author":"Arlt","year":"2003","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.ijgc.2025.104456_bib34","doi-asserted-by":"crossref","first-page":"15292","DOI":"10.18632\/oncotarget.24577","article-title":"Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-\u03baB","volume":"9","author":"Shirai","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ijgc.2025.104456_bib35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mc.22503","article-title":"Downregulation of STAT3\/NF-\u03baB potentiates gemcitabine activity in pancreatic cancer cells","volume":"56","author":"Gong","year":"2017","journal-title":"Mol Carcinog"},{"issue":"1","key":"10.1016\/j.ijgc.2025.104456_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jpi.12285","article-title":"Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-\u03baB activation","volume":"60","author":"Ju","year":"2016","journal-title":"J Pineal Res"},{"key":"10.1016\/j.ijgc.2025.104456_bib37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1471-2407-13-194","article-title":"Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer","volume":"13","author":"Yip-Schneider","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.104456_bib38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPA.0b013e318254f455","article-title":"Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer","volume":"42","author":"Yip-Schneider","year":"2013","journal-title":"Pancreas"},{"issue":"8","key":"10.1016\/j.ijgc.2025.104456_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/cancers10080251","article-title":"The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer","volume":"10","author":"Savant","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ijgc.2025.104456_bib40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial","volume":"27","author":"Lindemann","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.104456_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25035807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25035807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:23:06Z","timestamp":1785356586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25035807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1048891X25035807"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.104456","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elenagen, a p62\/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.104456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104456"}}